Why Reversal Cannot Be Instant
HS does not develop overnight. In most patients, the internal environment that drives it has been building for years — sometimes from adolescence. Gut dysfunction establishes itself gradually through cumulative dietary patterns, antibiotic exposure, and sustained stress. Hormonal imbalance compounds over time through metabolic adaptation and, in women with PCOS, through the progressive entrenchment of androgen excess and insulin resistance. Immune dysregulation deepens with each inflammatory cycle, recalibrating the threshold of the immune response downward until it reliably overreacts to minor follicular events.
A disease that has taken years to establish at this depth cannot be corrected in weeks. Not because the interventions available are insufficient, but because the biology being corrected operates at a pace that is determined by cellular regeneration timescales, microbiome succession rates, and endocrine system re-regulation — none of which can be meaningfully accelerated beyond the rates at which biological systems actually function. To expect reversal to be rapid is to misunderstand what is being reversed.
This is not an argument for accepting slow progress or tolerating a correction process that is genuinely ineffective. It is an argument for understanding what progress actually looks like in the context of HS — so that genuine movement in the right direction is not misinterpreted as insufficient, and abandoned before the correction has time to consolidate.
"HS is not a skin problem. It is a systemic inflammatory condition expressing through the skin."
What Reversal Actually Looks Like — The Early Markers
The first signs that genuine internal correction is occurring in HS are not necessarily visible on the skin. They are systemic — because what is changing is the internal environment, not the skin's current output of that environment's state. Patients who are trained to look for these markers are much better placed to recognise that correction is working than patients who are evaluating progress solely by whether lesions have cleared.
Reduced systemic inflammatory load typically manifests first as non-specific improvements in wellbeing: better sleep quality, reduced fatigue, less of the diffuse background ache or heaviness that many HS patients describe as a constant feature of their experience. These improvements are not dramatic. But they reflect a genuine reduction in the systemic inflammatory burden — the same burden that is feeding HS activity — and they typically precede any visible changes in lesion pattern by several weeks.
Changing lesion behaviour is the next marker to appear, and it is subtler than outright lesion clearance. Episodes that were previously deep, slow to evolve, and slow to resolve begin to resolve more quickly. Lesions that previously tracked toward abscess formation begin to abort earlier — remaining as nodules that soften and disperse rather than progressing to full rupture and discharge. The severity of individual episodes diminishes before their frequency does. This is meaningful progress — it indicates that the inflammatory amplification that characterises HS is reducing, even if new episodes are still occurring.
Interval lengthening is often the most clearly observable marker at this stage: the time between episodes extends. A patient who was experiencing near-continuous activity begins to have genuine periods of quiescence — days, then weeks, without a new lesion initiating. These intervals initially feel fragile and are often accompanied by anxious monitoring for the next episode. Over time, as they lengthen and become more consistent, they represent the most tangible evidence that the internal environment is changing in a way that is reducing the frequency of HS generation.
The Significance of Partial Progress
One of the most clinically important aspects of HS reversal is what might be called the partial progress problem: the point at which the disease is genuinely better — less frequent, less severe, less impactful — but not yet in the state of sustained remission that was the goal of treatment. This is the point at which many patients make a consequential error.
Feeling meaningfully better, but not yet fully resolved, some patients discontinue the correction programme. The improvement has been sufficient to reduce the urgency that drove them to seek treatment. The remaining disease activity, while present, is manageable enough that it does not demand the same level of commitment to the correction programme. And so the programme is discontinued — or significantly reduced — before the internal correction has been fully established.
What follows is predictable: the internal drivers, which were partially corrected but not fully stabilised, resume their previous trajectory. Gut function, without continued support, drifts back toward its earlier pattern. Hormonal regulation, without the dietary and formulation support that was producing improvement, destabilises. The disease, deprived of the correction that was reducing its internal conditions, re-establishes its previous activity level — sometimes within weeks, sometimes over months.
This is the source of many patients' experience of treatments that "worked for a while then stopped working." The treatment did not stop working. The patient stopped the treatment — at the point of partial improvement rather than consolidated correction. Understanding this pattern changes what decisions are made at the partial progress stage.
Classical Ayurvedic clinical tradition distinguishes carefully between two endpoints of treatment: Shamana (palliation, or the reduction of symptoms) and Shodhana (purification, or the correction of the root imbalance). A patient at the partial progress stage has typically achieved Shamana — the symptoms have reduced to a manageable level. But Shodhana — the actual correction of the internal environment that was generating those symptoms — has not been completed. Discontinuing at Shamana ensures recurrence, because the driver of the symptoms remains active. Completing Shodhana changes the internal environment in a way that makes recurrence less likely, because the conditions that supported the disease no longer exist in the same form. The distinction is clinically critical, and it is the reason sustained correction, past the point of symptomatic improvement, is non-negotiable in the EPOH approach.
The Middle Phase — Consolidation
Once the early markers of reversal are established — reduced systemic inflammation, changing lesion behaviour, interval lengthening — the middle phase of correction focuses on consolidating these changes into a more stable internal state. This is where hormonal correction, tissue restoration, and more active immune regulation become the primary targets of treatment.
The middle phase is often the most variable in terms of patient experience. The initial dramatic improvements of the early phase have stabilised; the final consolidation of the later phase has not yet fully materialised. There is a period — lasting weeks to months depending on disease stage and the specific combination of drivers — in which progress feels less obvious than it did earlier, precisely because what is changing is internal stability rather than visible symptom reduction.
This phase requires a different kind of attention from patients. The early phase rewards close monitoring of lesion behaviour — changes are observable and provide immediate feedback on the direction of correction. The middle phase requires attention to less dramatic markers: energy levels, sleep quality, menstrual cycle regularity in women, the general sense of systemic stability that reflects a body whose regulatory systems are functioning with less disruption. These are harder to observe and measure than lesion frequency, but they are what genuine consolidation looks like internally.
What Sustained Remission Looks Like
Sustained remission in HS — the outcome that represents the successful completion of internal correction — does not mean the permanent and complete absence of any HS activity for the rest of the patient's life, regardless of what they do. It means a state in which the internal environment has been sufficiently corrected that HS requires a meaningful trigger — a significant disruption of gut function, a hormonal perturbation, a period of sustained stress — to generate new activity, rather than operating continuously from a baseline internal state that reliably produces it.
The distinction matters. Patients in sustained remission can and do experience occasional episodes — particularly during periods of significant life stress, dietary disruption, or hormonal flux. These episodes are typically less severe than the disease before correction, and they typically resolve more quickly, because the immune system is operating from a more regulated baseline and the systemic inflammatory burden is lower. They are signals of temporary disruption, not evidence that the correction has failed.
What is absent in sustained remission — what distinguishes it from the managed disease state that most patients arrive with — is the continuous, background generation of new lesions from an uncorrected systemic driver. The episodic nature of HS in remission reflects a disease that requires specific triggers to generate activity, rather than one that generates it reliably as a consequence of an internal state that has never been corrected.
Measuring Progress — What to Track and When
The most useful measure of progress in HS reversal is not lesion clearance, which is a lagging indicator. By the time the skin reflects internal improvement, the internal changes that produced that improvement have already been underway for weeks or months. Tracking the skin too closely — particularly in the early phases — creates the impression of stagnation when genuine internal movement is actually occurring.
More useful markers, tracked over intervals of four to six weeks rather than day by day, include: the frequency of new lesion initiation; the average severity of episodes when they do occur; the time from initiation to resolution; the length of quiescent intervals; and the overall systemic markers of inflammatory burden — energy, sleep, and the diffuse background discomfort that many patients describe as the ambient experience of living with active HS.
Tracking these markers over months rather than weeks reveals a trajectory. And a trajectory — even one that is non-linear, that includes temporary worsening and unexpected plateau periods — is what reversal actually looks like from the inside. The question is not whether any given week is better or worse than the previous week. The question is whether the six-month picture is meaningfully different from the six-month picture that preceded the correction. In a genuine reversal process, it will be.
"When a condition keeps recurring, it usually follows an underlying pattern that needs to be understood and addressed — not suppressed."
Why Reversal Is Worth the Time It Takes
The most common objection to an approach that is honest about the timescale of HS reversal is a reasonable one: why commit to a process that takes months when suppression can produce apparent improvement in days or weeks? The answer is equally reasonable: because suppression that leaves the internal drivers intact produces a cycle — temporary improvement, relapse, more treatment — that can continue indefinitely. A disease managed through suppression does not get better over years. It typically worsens, as the tissue consequences accumulate and the internal drivers, left uncorrected, progressively deepen their influence.
Reversal — genuine internal correction — is slower. But it is also cumulative. Each phase of correction that is completed and consolidated represents a genuine change in the internal environment that does not reverse when the treatment is stopped. A gut that has been restored functions differently from a gut that has simply been worked around. A hormonal balance that has been re-established produces a different follicular environment than one that has been temporarily suppressed. The correction, once genuinely made, holds in a way that suppression does not.
This is what makes the investment of time required for genuine HS reversal different from the investment of time that goes into managing a disease that is not being corrected. Management without correction is open-ended — it continues for as long as the disease does. Correction, properly sequenced and sustained to completion, ends the open-ended cycle by changing what is generating it.